The per-vial charts below pair common target doses with practical water volumes and syringe marks
10 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 ADA=American Diabetes Association
Verify any product against a third-party Certificate of Analysis
Common injection sites include the abdomen (at least 2 inches from the navel), the front of the thighs, and the back of the upper arms (if someone else is administering)
This treatment is especially useful for individuals with low energy, poor concentration, or conditions that limit B12 absorption from food or supplements
Please note: For Intramuscular (IM) or Intravenous (IV) use only Store away from direct sunlight 1 ~ 25C Keep out of sight and reach of children Not intended to diagnose, treat, cure or prevent any disease, for promoting wellness only This is a single use ampoule, once opened, use immediately and discard any product not used All products are for sale to trained and insured professionals only who are 18+ years of age
